Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -39.73% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 296.32% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -53.57% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -246.81% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.84% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -40.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.87% |
| Mar 31, 2026 | -29.08% |
| Dec 31, 2025 | -44.31% |
| Sep 30, 2025 | 93.36% |
| Jun 30, 2025 | 47.55% |
| Mar 31, 2025 | 251.34% |
| Dec 31, 2024 | 171.66% |
| Sep 30, 2024 | 289.69% |
| Jun 30, 2024 | -324.44% |
| Mar 31, 2024 | -26.07% |
| Dec 31, 2023 | 121.04% |
| Sep 30, 2023 | 128.44% |
| Jun 30, 2023 | 41.92% |
| Mar 31, 2023 | 43.17% |
| Dec 31, 2022 | -108.67% |
| Sep 30, 2022 | -71.38% |
| Jun 30, 2022 | 20.63% |
| Mar 31, 2022 | -26.32% |
| Dec 31, 2021 | -26.30% |
| Sep 30, 2021 | 21.02% |